Qingran H. Yan

145 Shandong Middle Road, 2000001
Shanghai, 200000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.

Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.

Journal: Frontiers in immunology
Published: May 17, 2024

GexMolGen: cross-modal generation of hit-like molecules via large language model encoding of gene expression signatures.

GexMolGen: cross-modal generation of hit-like molecules via large language model encoding of gene expression signatures.

Journal: Briefings in bioinformatics
Published: May 07, 2024

Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.

Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.

Journal: Annals of the rheumatic diseases
Published: February 05, 2024

Correction: Iguratimod attenuated fbrosis in systemic sclerosis via targeting early growth response 1 expression.

Correction: Iguratimod attenuated fbrosis in systemic sclerosis via targeting early growth response 1 expression.

Journal: Arthritis research & therapy
Published: January 23, 2024

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression.

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression.

Journal: Arthritis research & therapy
Published: February 01, 2023

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis.

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 13, 2022

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer.

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer.

Journal: Frontiers in medicine
Published: December 01, 2022

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study.

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study.

Journal: Frontiers in immunology
Published: October 06, 2022

Duration biased distribution of clinical and immunological phenotypes in active SLE.

Duration biased distribution of clinical and immunological phenotypes in active SLE.

Journal: Frontiers in immunology
Published: September 14, 2022

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.

Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: September 10, 2022

Quantitative infrapatellar fat pad signal intensity alteration as an imaging biomarker of knee osteoarthritis progression.

Quantitative infrapatellar fat pad signal intensity alteration as an imaging biomarker of knee osteoarthritis progression.

Journal: RMD open
Published: July 13, 2022

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome.

Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 16, 2022
Showing 1-12 of 31

Last Updated: 09/26/2026